# AI Hidden Gems Discovery Report
**Date:** October 6, 2025
**Sector:** AI Stocks (General AI Sector)
**Market Cap Limit:** <$5B
**Stocks Analyzed:** 10
**Final Recommendations:** 4

---

## üéØ Executive Summary

**Discovery Method:** Multi-round agentic research via Perplexity Pro Search
**Research Rounds Completed:** 2 of 8 (Broad Discovery + Financial Screening)
**Screening Criteria:**
- Market cap <$5B
- Low analyst coverage (<10 analysts)
- Strong recent AI developments or catalysts
- Reasonable liquidity (>100K volume/day)
- Sector alignment: AI chips, infrastructure, software, edge AI, data centers

**Top Picks (4 stocks):**
1. **INOD** - Innodata ‚≠ê **TOP HIDDEN GEM** - Pure AI data services, 79% revenue growth, PROFITABLE
2. **ASYS** - Amtech Systems - Zacks #1 Strong Buy, AI chip equipment maker
3. **PD** - PagerDuty - DevOps + AI automation, value opportunity
4. **RXRX** - Recursion Pharma - AI drug discovery, high-risk/high-reward

**Disqualified (3 stocks exceeded $5B cap):** RGTI ($11-13B), SOUN ($7.3B), OSCR ($5-6B)

---

## üìä Final Recommendations

### Tier 1: High Conviction Hidden Gems

#### INOD - Innodata Inc. ‚≠ê **TOP PICK**
**Market Cap:** ~$1.5B | **Price:** TBD | **Analyst Coverage:** 2 analysts

**Why It's a Hidden Gem:**
- **Only 2 analysts covering** - true under-the-radar play
- **79% YoY revenue growth** - Q2 2025 revenue $58.4M
- **PROFITABLE** - Adjusted EBITDA $13.2M (up 375% YoY)
- **Raised guidance** - 45% organic growth (from 40%)
- **Pure AI play** - Generative AI services, data annotation, Agentic AI

**Financials (Q2 2025):**
- Revenue: $58.4M (up 79% YoY)
- Adjusted EBITDA: $13.2M (up 375% YoY)
- FY2025 Guidance: 45% organic revenue growth
- Major Client Wins: New $10M client expected H2 2025
- Customer Growth: One relationship grew $200K ‚Üí $10M in 1 year

**Recent Catalysts:**
- Won second Statement of Work from largest customer
- Multiple new projects from major tech clients
- Strong momentum in generative AI and Agentic AI services

**Entry Strategy:**
- **Recommended Entry Zone:** Research TBD (run `/deep-stock-research INOD`)
- **Current Status:** Further analysis needed
- **Risk Level:** Medium (customer concentration risk)
- **Position Size:** 2-3% max

**Risks:**
- Customer concentration (largest customer critical)
- Needs diversification
- Only 2 analysts (less coverage = less liquidity)

**Next Steps:**
1. Run comprehensive research: `/deep-stock-research INOD --type=comprehensive`
2. Monitor Q3 2025 earnings for guidance updates
3. Verify customer diversification progress

**Comprehensive Research:** Recommended before entry

---

#### ASYS - Amtech Systems Inc.
**Market Cap:** ~$100-200M (small-cap) | **Analyst Coverage:** 6 analysts

**Why It's a Hidden Gem:**
- **Zacks Rank #1 Strong Buy** - Top-rated by Zacks
- **AI equipment sales up 5x** - Now 25% of Thermal Processing revenue
- **Returned to profitability** - Q3 FY2025: $0.06 EPS (vs -$0.16 loss)
- **Sequential growth accelerating** - Revenue up 26% Q-over-Q

**Financials (Q3 FY2025):**
- Revenue: $19.6M (up 26% sequentially)
- Earnings: $0.06 per share (vs -$0.16 loss prior quarter)
- AI Equipment Revenue: 25% of Thermal Processing Solutions
- Growth Rate: 5x YoY in AI-related equipment sales

**Business:**
Semiconductor equipment maker supplying thermal processing, chemical-mechanical polishing (CMP), and advanced chip packaging tools essential for AI chip fabrication, including GPUs and silicon carbide semiconductors.

**Recent Catalysts:**
- Oracle earnings report highlighted massive hyperscaler AI infrastructure demand
- Analysts revising estimates higher following Oracle's guidance
- AI equipment becoming material portion of revenue (25%)

**Entry Strategy:**
- **Recommended Entry Zone:** TBD (needs technical analysis)
- **Risk Level:** Medium
- **Position Size:** 2-3% max
- **Catalyst:** Q4 FY2025 earnings (date TBD)

**Risks:**
- Small-cap volatility
- Semiconductor equipment cycles
- Revenue concentration in AI may be temporary

**Next Steps:**
1. Run comprehensive research for entry zones
2. Monitor semiconductor equipment spending trends
3. Track AI chip manufacturing capacity expansion announcements

**Comprehensive Research:** `~/dotfiles/research/stocks/2025-10/ASYS/` (run `/deep-stock-research ASYS`)

---

### Tier 2: Watch List (Conditional Buy)

#### PD - PagerDuty Inc.
**Market Cap:** $1.49-1.56B | **Analyst Coverage:** Moderate

**Why It's Interesting:**
- Established DevOps platform integrating AI for incident management
- Market cap down 44.71% since IPO - **potential value opportunity**
- AI-powered capabilities for IT operations management and automation
- Adequate trading volume for position building

**Business:**
IT operations management, incident response, and automation platform with AI-powered capabilities. Handles complex technical operations across thousands of enterprises.

**Entry Strategy:**
- **Current Status:** Value play - significantly down from highs
- **Risk Level:** Medium
- **Position Size:** 2-3% max
- **Catalyst Needed:** Proof of AI product adoption driving revenue growth

**Risks:**
- Competitive DevOps market
- Needs to demonstrate AI differentiation
- Stock price decline may indicate fundamental issues

**Next Steps:**
1. Analyze recent earnings for AI revenue contribution
2. Compare valuation to peers (Datadog, Splunk, etc.)
3. Assess competitive moat

**Comprehensive Research:** Needed before entry

---

#### RXRX - Recursion Pharmaceuticals Inc.
**Market Cap:** $2.01-2.42B | **Analyst Coverage:** 5 analysts (Hold consensus)

**Why It's Interesting:**
- AI-driven drug discovery platform for cancer therapies
- Recent momentum: Up 19% past week, 18.5% past 30 days
- Trading volume: 25M+ shares daily (highly liquid)
- AI + pharma intersection - unique positioning

**Business:**
AI-driven drug discovery platform using machine learning for pharmaceutical research, focused on cancer therapies. Several cancer candidates in early-phase clinical trials.

**Recent Catalysts:**
- Stock recovering after difficult year (down 23.4% YTD)
- AI-accelerated drug discovery showing progress
- Partnership with Nvidia (supercomputer-scale resources)

**Entry Strategy:**
- **Risk Level:** HIGH (biotech binary outcomes)
- **Position Size:** 1-2% max (speculation only)
- **Not Recommended For:** Conservative investors
- **Catalyst:** Clinical trial results (binary outcomes)

**Risks:**
- **High cash burn** - unclear runway
- **Binary outcomes** - clinical trial dependent
- **Analysts:** "Too risky for most investors"
- **Uncertain timeline** to commercialization
- Down 23.4% YTD despite recent bounce

**Next Steps:**
1. Monitor clinical trial progress
2. Track cash burn rate and need for future funding
3. Only enter with speculative capital (1% max)

**Comprehensive Research:** High priority due to extreme risk

---

## üö´ Tier 3: Disqualified (Market Cap Exceeded)

### RGTI - Rigetti Computing
**Market Cap:** ~$11-13B (EXCEEDS $5B threshold)
**Reason for Disqualification:** Too large for "hidden gem" criteria

**Notable Data:**
- Analyst Coverage: 5 analysts
- Revenue: $1.8M quarterly (pre-commercial)
- Valuation: 900x P/S ratio (extreme speculation)
- Stock Performance: Up 4,000% past year
- Cash Position: $571M, no debt
- Recent Milestone: 36-qubit processor (99.5% gate fidelity)

**Assessment:** Quantum computing pure play, highly speculative. May be worth monitoring if market cap falls below $5B, but current valuation is extreme.

---

### SOUN - SoundHound AI
**Market Cap:** $7.27-7.53B (EXCEEDS $5B threshold)
**Reason for Disqualification:** Too large

**Notable Data:**
- Analyst Coverage: 7-8 analysts
- Q1 2025 Revenue: $29.1M (up 151% YoY)
- FY2025 Guidance: $157-177M (85-109% growth)
- Cash: $246M, no debt
- Recent Acquisitions: SYNQ3, Allset, Amelia (+$45M recurring revenue)
- Partnerships: NVIDIA, Tencent, Perplexity AI

**Assessment:** Strong voice AI platform with explosive growth, but no longer qualifies as "hidden gem" due to market cap and analyst coverage.

---

### OSCR - Oscar Health
**Market Cap:** ~$5-6B (AT/ABOVE threshold)
**Reason for Disqualification:** Borderline too large, plus red flags

**Red Flags:**
- 7 analysts with consensus **Sell rating**
- Primarily healthcare/insurance, not pure AI play
- Regulatory-sensitive (ACA subsidy dependency)
- AI is component, not core business model

**Assessment:** Not recommended even if market cap qualifies. Weak fundamentals and regulatory risk.

---

## üìã Research Methodology

### Round 1: Broad Discovery
**Query:** Discover hidden gem AI stocks under $5B with low analyst coverage
**Results:** 10 initial candidates identified across AI chips, infrastructure, software, quantum computing, and AI-enabled sectors
**Sources:** 28+ sources (Zacks, AOL, Nasdaq, Forbes, Yahoo Finance, timothysykes, stockstotrade)

### Round 2: Financial Screening
**Query:** Comprehensive financial data including revenue, profitability, balance sheet, valuation, customer concentration, analyst coverage, trading volume
**Results:** Narrowed to 4 stocks meeting all criteria (INOD, ASYS, PD, RXRX)
**Disqualified:** 3 stocks exceeded $5B market cap; 1 stock had too many analysts
**Sources:** 53+ sources including SEC filings, analyst reports, market data providers

**Rounds 3-8 Not Completed:**
Due to token constraints, the following hedge fund-grade analyses were not performed:
- Round 3: Catalyst & Momentum Analysis
- Round 4: Leadership & Governance + Capital Allocation
- Round 5: Insider Trading & Institutional Ownership
- Round 6: Patent & R&D Productivity
- Round 7: Risk Assessment
- Round 8: Entry Zones & Valuation

**Recommendation:** Run individual `/deep-stock-research` on top picks (INOD, ASYS) to complete comprehensive analysis before investing.

---

## üîç Comparison Matrix

| Stock | Mkt Cap | P/S | Rev Growth | Profitable | Analyst Coverage | Risk | Hidden Gem Score |
|-------|---------|-----|------------|------------|------------------|------|------------------|
| **INOD** | $1.5B | TBD | +79% YoY | ‚úÖ Yes | 2 | Med | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê |
| **ASYS** | $100-200M | TBD | +26% Seq | ‚úÖ Yes | 6 | Med | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê |
| **PD** | $1.49B | TBD | TBD | TBD | Mod | Med | ‚≠ê‚≠ê‚≠ê |
| **RXRX** | $2.01B | TBD | TBD | ‚ùå No | 5 | High | ‚≠ê‚≠ê |

**Hidden Gem Score Criteria:**
- ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê = Exceptional (only 2-6 analysts, strong growth, profitable, pure AI play)
- ‚≠ê‚≠ê‚≠ê‚≠ê = Strong (meets all criteria, good fundamentals)
- ‚≠ê‚≠ê‚≠ê = Solid (meets criteria, some concerns)
- ‚≠ê‚≠ê = Speculative (high risk, conditional buy)

---

## üí° Portfolio Construction Recommendation

**Conservative Portfolio ($50K):**
- **INOD:** $2,000 (4%) - Top pick, wait for entry zone
- **ASYS:** $1,500 (3%) - Zacks #1 Strong Buy
- **Cash:** $46,500 (93%) - Wait for remaining stocks' comprehensive research

**Aggressive Portfolio ($50K):**
- **INOD:** $2,500 (5%)
- **ASYS:** $2,000 (4%)
- **PD:** $1,500 (3%)
- **RXRX:** $500 (1%) - Speculation only
- **Cash:** $43,500 (87%)

**Recommendation:** Run comprehensive research on all 4 stocks before deploying capital. Entry zones, stop losses, and detailed risk analysis needed.

---

## üö® Important Disclaimers

**Discovery Limitations:**
- Research based on Perplexity data as of October 6, 2025
- Only 2 of 8 planned research rounds completed
- Market conditions can change rapidly
- Small/mid-cap AI stocks are inherently volatile
- Lower liquidity = wider bid-ask spreads
- Always verify financials independently via 10-K/10-Q filings

**Missing Analyses (Rounds 3-8 not completed):**
- No leadership/governance analysis
- No insider trading or institutional ownership review
- No patent analysis or R&D productivity assessment
- No comprehensive risk assessment
- No entry zones or technical analysis
- No capital allocation track record review

**Risk Warnings:**
- Hidden gems = higher volatility and risk
- Analyst coverage is low = less information available
- Company-specific risks not fully analyzed
- AI sector risks: competition, technology shifts, hype cycles
- **INOD:** Customer concentration risk
- **ASYS:** Semiconductor cycle risk
- **RXRX:** Biotech binary outcome risk (clinical trials)

**Before Investing:**
1. Run `/deep-stock-research {TICKER} --type=comprehensive` for each stock
2. Verify financial data via official SEC filings
3. Check recent news and earnings transcripts
4. Determine appropriate position sizes based on your risk tolerance
5. Set stop losses (recommended: 7-10% below entry)

---

## üìù Next Steps for Investor

1. **Prioritize comprehensive research:**
   - `/deep-stock-research INOD --type=comprehensive` (TOP PRIORITY)
   - `/deep-stock-research ASYS --type=comprehensive`

2. **Create watch list and set alerts:**
   - Run daily updates to determine entry zones
   - Set price alerts at identified entry levels

3. **Monitor upcoming catalysts:**
   - INOD: Q3 2025 earnings (date TBD)
   - ASYS: Q4 FY2025 earnings (date TBD)

4. **Verify through official channels:**
   - Read latest 10-K/10-Q filings on SEC.gov
   - Review investor presentations on company IR sites
   - Check insider trading activity (Form 4 filings)

5. **Start with small positions** (1-2% per stock max initially)

6. **Create portfolio CSV** if adopting multiple stocks:
   ```
   ~/dotfiles/research/stocks/portfolios/AI-hidden-gems.csv
   ```

---

## üîó Related Research

**Individual Stock Reports (To Be Generated):**
- Run: `/deep-stock-research INOD --type=comprehensive`
- Run: `/deep-stock-research ASYS --type=comprehensive`
- Run: `/deep-stock-research PD --type=comprehensive`
- Run: `/deep-stock-research RXRX --type=comprehensive`

**Sector Analysis:**
- AI sector trends and outlook
- Competitor analysis for each stock

---

## üìã Audit Trail

**Discovery Process:**
- **Research Rounds:** 2 of 8 completed
- **Total Stocks Screened:** 10
- **Final Recommendations:** 4
- **Research Duration:** ~90 minutes
- **Data Sources:** Perplexity AI (company filings, financial news, analyst reports, market data)

**Raw Research Data:** Available in `./raw-discovery/2025-10-06/` directory
- `00-session-metadata.json` - Session info and completion status
- `01-round1-broad-discovery.md` - Initial 10 candidates with screening
- `02-round2-financial-screening.md` - Comprehensive financial analysis

**Incomplete Rounds:** 3-8 not executed due to token constraints. Individual stock research recommended to fill gaps.

---

**Generated:** October 6, 2025, 4:15 PM PDT
**Next Discovery Run:** Quarterly (January 2026) or when AI sector corrects 15%+
**Discovery Command:** `/discover-stocks AI stocks`

---

## üìû Quick Reference

**Top Pick:** INOD - Innodata ($1.5B, 2 analysts, 79% growth, PROFITABLE) ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê

**Safest Pick:** ASYS - Amtech Systems (Zacks #1 Strong Buy, small but profitable)

**Value Play:** PD - PagerDuty (down 45% from highs, established platform)

**Speculation:** RXRX - Recursion (AI+pharma, 1% max position, high risk)

**Action Items:**
1. Research INOD comprehensively (TOP PRIORITY)
2. Research ASYS for entry zones
3. Monitor PD earnings for AI traction
4. Track RXRX clinical trials (speculative only)
